The breast cancer diagnostics market size has grown strongly in recent years. It will grow from $5 billion in 2025 to $5.42 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising incidence of breast cancer globally, increased awareness of early cancer screening, expansion of diagnostic imaging infrastructure, growing availability of biomarker-based tests, improvements in biopsy accuracy and safety.
The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $7.28 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising investments in AI-enabled diagnostic platforms, growing demand for minimally invasive testing, expansion of population-based screening programs, continuous advancements in molecular diagnostic technologies. Major trends in the forecast period include increasing adoption of ai-assisted imaging analysis, rising use of genomic and molecular testing, growing deployment of liquid biopsy techniques, expansion of advanced non-ionizing imaging modalities, enhanced focus on early and personalized diagnosis.
Government initiatives and funding for breast cancer are expected to drive growth in the breast cancer diagnostics market in the coming years. Such initiatives provide financial support to programs or projects that contribute to public health and economic development. These efforts play a crucial role in supporting breast cancer research, prevention, and treatment by raising awareness, promoting early detection through screening and mammography, and offering financial assistance to underserved communities for testing and treatment. For example, in its 2022-23 budget, the Australian Government Department of Health allocated $40.7 million to improve accessibility to testing and screening services for various cancers, addressing setbacks caused by the COVID-19 pandemic, and enabling timely referrals, prompt diagnosis, and early intervention. Of this, $9.7 million was specifically dedicated to breast cancer screening. Therefore, government initiatives and funding are supporting the expansion of the breast cancer diagnostics market.
Major companies operating in the breast cancer diagnostics market are focusing on AI-driven innovations to improve diagnostic accuracy, streamline workflows, and support personalized treatment planning. AI-based diagnostic platforms use machine learning and deep-learning algorithms to analyze medical imaging, pathology slides, or clinical data, providing insights and risk stratifications that aid clinical decision-making. For instance, in September 2024, Ibex Medical Analytics, an Israel-based digital pathology company, expanded its AI platform for breast cancer diagnostics by introducing a fully automated zero-click HER2 immunohistochemistry (IHC) scoring feature in its Ibex Breast HER2 module. This tool identifies invasive cancer regions, classifies HER2 expression levels (0, 1+, 2+, 3+), and supports breast cancer diagnosis and treatment decisions with enhanced accuracy and workflow efficiency.
In July 2024, Hologic Inc., a US-based healthcare technology company, acquired Endomagnetics Ltd. for $310 million. This acquisition strengthens Hologic’s breast surgery portfolio by integrating Endomag’s wireless localization and lymphatic tracing solutions. Endomagnetics Ltd., based in the UK, provides advanced technologies for breast cancer diagnostics, including tissue localization and lymphatic mapping solutions.
Major companies operating in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.
North America was the largest region in the breast cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the breast cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the breast cancer diagnostics market by increasing costs of imported imaging systems, genomic testing kits, reagents, biopsy devices, and advanced laboratory equipment. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported high-value diagnostic technologies, while Asia-Pacific faces cost pressures on equipment procurement and test consumables. These tariffs are raising operational costs and slowing technology upgrades in some healthcare facilities. However, they are also encouraging local manufacturing of diagnostic kits, regional reagent production, and domestic innovation in imaging and molecular testing solutions.
The breast cancer diagnostics market research report is one of a series of new reports that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Breast cancer is a medical condition characterized by the uncontrolled proliferation of cells within the breast, often leading to the formation of lumps. Breast cancer diagnostic devices are designed for the purpose of identifying and confirming the presence of cancerous growth within the breast tissue.
Key categories within breast cancer diagnostics include various diagnostic methods such as imaging techniques, biopsies, genomic testing, blood tests, and other relevant approaches. Biopsy, a process involving the removal of tissue or cellular samples from the body for subsequent laboratory testing, is one of the primary diagnostic techniques employed in breast cancer cases. The technologies utilized for these diagnostic procedures encompass Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC) techniques, along with others. Breast cancer exhibits diverse types, including BRCA breast cancer, ER and PR breast cancer, HER2-positive breast cancer, EGFR mutation test breast cancer, and additional variants. Breast cancer diagnostics are further categorized into ionizing breast imaging technologies and non-ionizing imaging technologies. The end-users of these diagnostic services encompass hospitals and clinics, cancer research centers, diagnostic laboratories, as well as ambulatory surgical centers.
The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $7.28 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising investments in AI-enabled diagnostic platforms, growing demand for minimally invasive testing, expansion of population-based screening programs, continuous advancements in molecular diagnostic technologies. Major trends in the forecast period include increasing adoption of ai-assisted imaging analysis, rising use of genomic and molecular testing, growing deployment of liquid biopsy techniques, expansion of advanced non-ionizing imaging modalities, enhanced focus on early and personalized diagnosis.
Government initiatives and funding for breast cancer are expected to drive growth in the breast cancer diagnostics market in the coming years. Such initiatives provide financial support to programs or projects that contribute to public health and economic development. These efforts play a crucial role in supporting breast cancer research, prevention, and treatment by raising awareness, promoting early detection through screening and mammography, and offering financial assistance to underserved communities for testing and treatment. For example, in its 2022-23 budget, the Australian Government Department of Health allocated $40.7 million to improve accessibility to testing and screening services for various cancers, addressing setbacks caused by the COVID-19 pandemic, and enabling timely referrals, prompt diagnosis, and early intervention. Of this, $9.7 million was specifically dedicated to breast cancer screening. Therefore, government initiatives and funding are supporting the expansion of the breast cancer diagnostics market.
Major companies operating in the breast cancer diagnostics market are focusing on AI-driven innovations to improve diagnostic accuracy, streamline workflows, and support personalized treatment planning. AI-based diagnostic platforms use machine learning and deep-learning algorithms to analyze medical imaging, pathology slides, or clinical data, providing insights and risk stratifications that aid clinical decision-making. For instance, in September 2024, Ibex Medical Analytics, an Israel-based digital pathology company, expanded its AI platform for breast cancer diagnostics by introducing a fully automated zero-click HER2 immunohistochemistry (IHC) scoring feature in its Ibex Breast HER2 module. This tool identifies invasive cancer regions, classifies HER2 expression levels (0, 1+, 2+, 3+), and supports breast cancer diagnosis and treatment decisions with enhanced accuracy and workflow efficiency.
In July 2024, Hologic Inc., a US-based healthcare technology company, acquired Endomagnetics Ltd. for $310 million. This acquisition strengthens Hologic’s breast surgery portfolio by integrating Endomag’s wireless localization and lymphatic tracing solutions. Endomagnetics Ltd., based in the UK, provides advanced technologies for breast cancer diagnostics, including tissue localization and lymphatic mapping solutions.
Major companies operating in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.
North America was the largest region in the breast cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the breast cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the breast cancer diagnostics market by increasing costs of imported imaging systems, genomic testing kits, reagents, biopsy devices, and advanced laboratory equipment. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported high-value diagnostic technologies, while Asia-Pacific faces cost pressures on equipment procurement and test consumables. These tariffs are raising operational costs and slowing technology upgrades in some healthcare facilities. However, they are also encouraging local manufacturing of diagnostic kits, regional reagent production, and domestic innovation in imaging and molecular testing solutions.
The breast cancer diagnostics market research report is one of a series of new reports that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Breast cancer is a medical condition characterized by the uncontrolled proliferation of cells within the breast, often leading to the formation of lumps. Breast cancer diagnostic devices are designed for the purpose of identifying and confirming the presence of cancerous growth within the breast tissue.
Key categories within breast cancer diagnostics include various diagnostic methods such as imaging techniques, biopsies, genomic testing, blood tests, and other relevant approaches. Biopsy, a process involving the removal of tissue or cellular samples from the body for subsequent laboratory testing, is one of the primary diagnostic techniques employed in breast cancer cases. The technologies utilized for these diagnostic procedures encompass Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC) techniques, along with others. Breast cancer exhibits diverse types, including BRCA breast cancer, ER and PR breast cancer, HER2-positive breast cancer, EGFR mutation test breast cancer, and additional variants. Breast cancer diagnostics are further categorized into ionizing breast imaging technologies and non-ionizing imaging technologies. The end-users of these diagnostic services encompass hospitals and clinics, cancer research centers, diagnostic laboratories, as well as ambulatory surgical centers.
The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Breast Cancer Diagnostics Market Characteristics
3. Breast Cancer Diagnostics Market Supply Chain Analysis
4. Global Breast Cancer Diagnostics Market Trends and Strategies
5. Breast Cancer Diagnostics Market Analysis of End Use Industries
7. Global Breast Cancer Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Breast Cancer Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Breast Cancer Diagnostics Market Segmentation
10. Breast Cancer Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Breast Cancer Diagnostics Market
12. China Breast Cancer Diagnostics Market
13. India Breast Cancer Diagnostics Market
14. Japan Breast Cancer Diagnostics Market
15. Australia Breast Cancer Diagnostics Market
16. Indonesia Breast Cancer Diagnostics Market
17. South Korea Breast Cancer Diagnostics Market
18. Taiwan Breast Cancer Diagnostics Market
19. South East Asia Breast Cancer Diagnostics Market
20. Western Europe Breast Cancer Diagnostics Market
21. UK Breast Cancer Diagnostics Market
22. Germany Breast Cancer Diagnostics Market
23. France Breast Cancer Diagnostics Market
24. Italy Breast Cancer Diagnostics Market
25. Spain Breast Cancer Diagnostics Market
26. Eastern Europe Breast Cancer Diagnostics Market
27. Russia Breast Cancer Diagnostics Market
28. North America Breast Cancer Diagnostics Market
29. USA Breast Cancer Diagnostics Market
30. Canada Breast Cancer Diagnostics Market
31. South America Breast Cancer Diagnostics Market
32. Brazil Breast Cancer Diagnostics Market
33. Middle East Breast Cancer Diagnostics Market
34. Africa Breast Cancer Diagnostics Market
36. Breast Cancer Diagnostics Market Competitive Landscape and Company Profiles
37. Breast Cancer Diagnostics Market Other Major and Innovative Companies
40. Breast Cancer Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Breast Cancer Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses breast cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for breast cancer diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The breast cancer diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Imaging; Biopsy; Genomic Tests; Blood Tests; Other Types2) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
3) By Cancer Type: BRCA Breast Cancer; ER And PR Breast Cancer; HER 2 Breast Cancer; Triple-Negative Breast Cancer; Other Cancer Types
4) By Diagnostic Type: Ionizing Breast Imaging Technologies; Non-ionizing Imaging Technologies
5) By End Users: Hospitals And Clinics; Cancer Research Centers; Diagnostic Laboratories; Ambulatory Surgical Centers
Subsegments:
1) By Imaging: Mammography; Ultrasound Imaging; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET); Tomosynthesis2) By Biopsy: Needle Biopsy; Core Needle Biopsy; Fine Needle Aspiration Biopsy (FNA); Stereotactic Biopsy
3) By Genomic Tests: Oncotype DX; MammaPrint; PAM50; BRCA1 Or 2 Testing
4) By Blood Tests: Liquid Biopsy; Circulating Tumor DNA (ctDNA) Tests; Circulating Tumor Cells (CTCs) Tests
5) By Other Types: Hormone Receptor Tests; HER2 Tests; Genetic Mutation Testing
Companies Mentioned: Abbott Laboratories; Myriad Genetics Inc.; Hologic Inc.; Koninklijke Philips N.V.; Fujifilm Holdings Corporation; GE Healthcare; Thermo Fisher Scientific Inc.; Siemens AG; NanoString Technologies Inc.; Gamma Medica Inc.; Aurora Imaging Technology Inc.; Dilon Technologies Inc.; Exact Sciences Corporation; F. Hoffmann-La Roche Ltd.; Micrima Limited; Provista Diagnostics Inc.; Leica Biosystems Nussloch GmbH; bioTheranostics Inc.; Bio-Rad Laboratories Inc.; Illumina Inc.; Biocept Inc.; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Cepheid; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Oncocyte Corporation; PerkinElmer Inc.; Sysmex Corporation; Veracyte Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Breast Cancer Diagnostics market report include:- Abbott Laboratories
- Myriad Genetics Inc.
- Hologic Inc.
- Koninklijke Philips N.V.
- Fujifilm Holdings Corporation
- GE Healthcare
- Thermo Fisher Scientific Inc.
- Siemens AG
- NanoString Technologies Inc.
- Gamma Medica Inc.
- Aurora Imaging Technology Inc.
- Dilon Technologies Inc.
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd.
- Micrima Limited
- Provista Diagnostics Inc.
- Leica Biosystems Nussloch GmbH
- bioTheranostics Inc.
- Bio-Rad Laboratories Inc.
- Illumina Inc.
- Biocept Inc.
- Quest Diagnostics Incorporated
- Agilent Technologies Inc.
- Cepheid
- Guardant Health Inc.
- Invitae Corporation
- Natera Inc.
- NeoGenomics Laboratories Inc.
- Oncocyte Corporation
- PerkinElmer Inc.
- Sysmex Corporation
- Veracyte Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.42 Billion |
| Forecasted Market Value ( USD | $ 7.28 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 33 |
